Acelot Therapeutics received $8.7 million to develop a new treatment for ALS, targeting a key protein called TDP-43, which malfunctions in ALS, to slow or stop disease progression.
Acelot Therapeutics received $8.7 million to develop a new treatment for ALS, targeting a key protein called TDP-43, which malfunctions in ALS, to slow or stop disease progression.
